Bookmark
Forward
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.
Amritpal Singh, Aref Al-Kali, James M Foran, Michelle A Elliott, Kebede Begna, Talha Badar, Nandita Khera, Farah Fleti, Maymona Abdelmagid, Kareen K Reichard, Rhett P Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
American journal of hematology 2022 OctSizes of these terms reflect their relevance to your search.
No abstract available.
Citation
Amritpal Singh, Aref Al-Kali, James M Foran, Michelle A Elliott, Kebede Begna, Talha Badar, Nandita Khera, Farah Fleti, Maymona Abdelmagid, Kareen K Reichard, Rhett P Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi. Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting. American journal of hematology. 2022 Oct;97(10):E377-E379
Mesh Tags
Substances
PMID: 35959963
View Full Text
